On Friday, the FDA approved Moderna Inc’s mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna ( MRNA ), the first being the famed COVID-19 vaccine....

01:17 PM EDT, 05/31/2024 (MT Newswires) -- S&P Global Ratings on Friday affirmed its ratings on CAE (CAE.TO), including its BBB- issuer credit rating on the company. The rating affirmation comes after CAE reported a re-baselining of its defense business, along with defense impairment charges and contract adjustments related to eight previously identified fixed-price legacy contracts. The stable outlook reflects...

01:16 PM EDT, 05/31/2024 (MT Newswires) -- S&P Global Ratings said Friday that it upgraded ratings on Fairfax Financial Holdings' ( FRFHF ) core re/insurance subsidiaries to A+ from A and on the holding company, Fairfax Financial Holdings ( FRFHF ) to BBB+ from BBB. The upgrade follows S&P's revised criteria for analyzing insurers' risk-based capital. The implementation of the...

01:21 PM EDT, 05/31/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday its Lorbrena drug for an advanced form of lung cancer helped patients live longer without disease progression, based on long-term follow-up results of a late-stage trial. Roughly 60% of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer and treated with Lorbrena were alive without disease...